Angus Dalgleish | |
|---|---|
 Dalgleish in 2016 | |
| Born | May 1950 (age 74) [1] Harrow, London, England |
| Alma mater | University College London |
| Employer | St George's, University of London |
| Known for | HIV/AIDS research [2] |
| Political party | UK Independence Party (UKIP) |
| Website | www |
Angus George Dalgleish (born May 1950) is a professor of oncology at St George's, University of London, best known for his contributions to HIV/AIDS research. [3] [4] [5] [6] Dalgleish stood in 2015 for Parliament as a UKIP candidate.
Angus George Dalgleish was born in May 1950 in Harrow, London. [1] [7] [8] Initially educated at the Harrow County School for Boys, [7] Dalgleish received a Bachelor of Medicine, Bachelor of Surgery degree from University College London with an intercalated bachelor's degree in Anatomy. [7]
After various positions in the United Kingdom, Dalgleish joined the Royal Flying Doctor Service in Mount Isa, Queensland, then progressed through positions at various hospitals in Brisbane, Australia, before moving to the Ludwig Institute for Cancer Research in Sydney. [7] [8]
After completion of his training, Dalgleish returned to work in the UK in 1984 at the Institute of Cancer Research. [7] [8] He is a co-discoverer of the CD4 receptor as the major cellular receptor for HIV. [9] [10] [11] [12] In 1986, he was appointed to a consulting position at Northwick Park Hospital, in 1991 he was made Foundation Professor of Oncology at St George's, University of London, [7] and in 1994 he was appointed Visiting Professor at the Institute of Cancer Research in London. [13]
In 1997, he founded Onyvax Ltd., [1] a privately-funded biotechnology company developing cancer vaccines, where he held the position as Research Director; [14] it was dissolved in 2013. [15] Dalgleish is a member of the medical board in Bionor Pharma.[ citation needed ] Dalgleish is on the scientific advisory board of Immodulon, and has stock options in Immunor AS, a disclosure he made in order to have his research work published. [16] [ non-primary source needed ]
During the COVID-19 pandemic, Dalgleish was a proponent of the lab leak theory. [17]
Dalgleish was a member of the UK Independence Party and stood as a candidate in Sutton & Cheam, [18] [19] during the 2015 United Kingdom general election finishing fourth with 10.7% of the vote. [20] Dalgleish campaigned for Leave.EU [21] and appeared on the BBC Radio 4 Today programme presenting the case for Brexit. [22] [18] [23] [24] He was an advocate of Leave Means Leave, a Eurosceptic group. [25]
Dalgleish was elected a Fellow of the Academy of Medical Sciences in 2001 [2] and is also a Fellow of the Royal College of Physicians [ when? ] the Royal College of Pathologists [ when? ] and a Fellow of the Royal Australasian College of Physicians.[ when? ] [23] His citation on election to FMedSci reads:
Professor Angus Dalgleish is Professor of Oncology at St Georges Hospital Medical School London. He has made seminal observations relating to the virology of HIV. In particular he identified CD4 as a major receptive for HIV in humans, produced the first report of a link between Slim Disease in Africa and HIV infection. He also identified the close correlation between the immune response and the presence of tropical spastic paraparesis in patients infected with the HTLV-1 virus. [2]
In October 2023, following a joint investigation analysing emails leaked in 2022 by Russian hacking group working for the Russian FSB, an article was published by Computer Weekly [26] and Byline Times [27] containing several controversial claims about Angus Dalgleish.
According to Semantic Scholar, Dalgleish has 495 publications, 21,234 citations, and 541 "highly influential citations". [30]
in Special Issue Cancer Immunotherapy and Vaccines Research
AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
Adenoviruses are medium-sized, nonenveloped viruses with an icosahedral nucleocapsid containing a double-stranded DNA genome. Their name derives from their initial isolation from human adenoids in 1953.
Luc Montagnier was a French virologist and joint recipient, with Françoise Barré-Sinoussi and Harald zur Hausen, of the 2008 Nobel Prize in Physiology or Medicine for his discovery of the human immunodeficiency virus (HIV). He worked as a researcher at the Pasteur Institute in Paris and as a full-time professor at Shanghai Jiao Tong University in China.
Sutton and Cheam is a constituency in Greater London represented in the House of Commons of the UK Parliament since 2024 by Luke Taylor, a Liberal Democrat.
Margaret Anne Stanley, OBE FMedSc, is a British virologist and epithelial biologist. She attended the Universities of London, Bristol, and Adelaide. As of 2018, she is an Emeritus Professor of Epithelial Biology in the Department of Pathology at the University of Cambridge and a Fellow of the Academy of Medical Sciences. She is also an Honorary Fellow of the UK Royal College of Obstetricians and Gynaecologists and an honorary fellow of Christ's College, Cambridge. Stanley is a research scientist in virology focusing on the human papillomavirus (HPV). Her research work has led to new scientific findings on HPV. Additionally, she uses her expertise on HPV to serve on multiple advisory committees and journal editorial boards.
Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Chang Yi Wang is the founder of United Biomedical, Inc. (UBI), headquartered in Hauppauge, New York, and its group of companies in Asia.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Big Pharma conspiracy theories are conspiracy theories that claim that pharmaceutical companies as a whole, especially big corporations, act in dangerously secretive and sinister ways that harm patients. This includes concealing effective treatments, perhaps even to the point of intentionally causing and/or worsening a wide range of diseases, in the pursuit of higher profits and/or other nefarious goals. The general public supposedly lives in a state of ignorance, according to such claims.
Paul Stuart Scully is a former British politician who served as the Member of Parliament (MP) for Sutton and Cheam from 2015 to 2024. A member of the Conservative Party, he served as Minister for London from February 2020 and Parliamentary Under-Secretary of State for Tech and the Digital Economy from October 2022. He was sacked from both roles in November 2023.
Dame Sarah Catherine Gilbert FRS is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).
The UK Coronavirus Cancer Programme or UKCCP is one of the longest running UK pandemic research programmes to safeguard, monitor and protect individuals living with cancer from COVID-19 across the United Kingdom.
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
Uğur Şahin is a German oncologist and immunologist. He is the co-founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.
Özlem Türeci is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology (HI-TRON) and Johannes Gutenberg University Mainz. Türeci and her spouse, Uğur Şahin, have won a number of awards.
The MRC Weatherall Institute of Molecular Medicine at the University of Oxford is a research institute located at the John Radcliffe Hospital in Oxford. Founded in 1989 by Sir David Weatherall, the institute focuses on furthering our understanding of clinical medicine at a molecular level. It was one of the first institutes of its kind in the world to be dedicated to research in this area.
Shabir Ahmed Madhi, is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwatersrand.
SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.
